| Specifications | |
|---|---|
| Product type | mRNA |
| Modified bases | 5-Methyl-CTP |
| 5' Cap | Cap 0 |
| Species | Human |
| RefSeq | NM_001134.3 |
| Applications | Gene therapy research |
| Format | Powder |
| Quantity | 100 µg |
| Purification | Chromatography |
| Target Gene | |
|---|---|
| Gene ID | 174 |
| UniProt ID | P02771 |
| Specifications | |
|---|---|
| Product type | mRNA |
| Modified bases | 5-Methyl-CTP |
| 5' Cap | Cap 0 |
| Species | Human |
| RefSeq | NM_001134.3 |
| Applications | Gene therapy research |
| Format | Powder |
| Quantity | 100 µg |
| Purification | Chromatography |
| Target Gene | |
|---|---|
| Gene ID | 174 |
| UniProt ID | P02771 |
| Download |
|---|
| Download resources about mRNA therapeutics development to boost your research. |
| CUSTOMER REVIEWS and Q&As | |
|---|---|
|
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human AFP, (Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WK10486MR). Click the button above to contact us or submit your feedback about this product. |
|
| See other products | |||
|---|---|---|---|
| CAT | Product Name | Product Type | CDs |
| GTTS-WK11196MR | IVTScrip™ mRNA-Human AC113404.1, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) | mRNA | AC113404.1 |
| GTTS-WK12994MR | IVTScrip™ mRNA-Human AC092159.2, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) | mRNA | AC092159.2 |
| GTTS-WK11485MR | IVTScrip™ mRNA-Human AC002467.7, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) | mRNA | AC002467.7 |
| GTTS-WK12098MR | IVTScrip™ mRNA-Human AC140481.1, (Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) | mRNA | AC140481.1 |
| GTTS-WK13630MR | IVTScrip™ mRNA-Human ACN9, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) | mRNA | ACN9 |
| GTTS-WK23428MR | IVTScrip™ mRNA-Human APOC1P1, (Cap 0, Pseudo-UTP, 30 nt-poly(A)) | mRNA | APOC1P1 |
| GTTS-WK1730MR | IVTScrip™ mRNA-Human human myeloid inhibitory C-lectin, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) | mRNA | hMICL |
| GTTS-WK13299MR | IVTScrip™ mRNA-Human AC241585.2, (Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) | mRNA | AC241585.2 |